Treatment of brain tumors
Brain tumors and other malignancies of the central nervous system are the second most common type in children accounting for 24 percent of all cancerous diseases developed at a young age. They are also the most common group of “solid” tumors.
Finding molecular targets for medication
The KiTZ is optimally equipped to accommodate the needs of children and young adults with brain tumors. In the department of Pediatric Brain Tumors, led by Prof. Dr. Olaf Witt, we provide care for our patients and their families in close collaboration with our colleagues from the departments of Pediatric Neurosurgery, Pediatric Neuroradiology, Radiation Therapy, Psychooncology und Neuropediatrics.
In collaboration with the department of Pediatric Neurooncology at the DKFZ, headed by Prof. Stefan Pfister, the Department of Neuropathology at the hospital, and with the help the of cutting edge molecular examination methods, we are able to conduct precise diagnoses of brain tumors as well as find “Targets“ (molecular target structures) for targeted therapies. These kinds of structures are particularly important for patients with recurring cancer.
In caring for our young patients, we use the most modern diagnostic and surgical methods available at the Heidelberg University Hospital. This also enables surgery on rare or inconveniently located tumors. In collaboration with the Heidelberg Ion Beam Therapy Center for Children and Young Adults (Kinder-HIT) we are often able to offer our brain tumor patients proton therapy.
Research and clinic working hand in hand
In order to translate new findings on the molecular causes of child brain tumors into targeted therapy concepts as quickly as possible, the physicians at the KiTZ work hand in hand with the researchers at the department of Pediatric Neurooncology and the Clinical Cooperation Unit “Pediatric Oncology” at the German Cancer Research Center (DKFZ) in Heidelberg.
Consultation „Brain tumors“
Prof. Dr. Till Milde, Prof. Dr. Stefan Pfister, Prof. Dr. Olaf Witt, Dr. Cornelis van Tilburg
Tel.: +49 6221 - 56 37082 (registration via the KiTZ Clinicial Trial Unit)